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Effectiveness of a Smoking Cessation
Program for Peripheral Artery Disease Patients
A Randomized Controlled Trial
Deborah Hennrikus, PHD,* Anne M. Joseph, MD, MPH,† Harry A. Lando, PHD,* Sue Duval, PHD,*
Laurie Ukestad, MS,‡ Molly Kodl, PHD,§ Alan T. Hirsch, MD*†
Minneapolis, Minnesota
Objectives This study tested the effectiveness of a smoking cessation program designed for patients with peripheral artery
disease (PAD).
Background Tobacco use is the leading risk factor for PAD incidence and progression and for ischemic events. Tobacco ces-
sation reduces PAD-related morbidity and mortality, yet few prospective clinical trials have evaluated smoking
cessation interventions in PAD patients.
Methods We recruited outpatients with lower extremity PAD identified from medical records as cigarette smokers. Partici-
pants were randomly assigned to an intensive tailored PAD-specific counseling intervention or a minimal inter-
vention. Participants completed surveys at baseline and at 3- and 6-month follow-up. Reported 7-day point prev-
alent smoking abstinence was confirmed by cotinine or carbon monoxide assessment.
Results In all, 687 outpatients were identified as probable smokers with lower extremity PAD; 232 met study eligibility
requirements; and 124 (53% of eligible) enrolled. Participants were receptive to counselor contact: the median
number of sessions was 8.5 (range 0 to 18). Participants randomly assigned to the intensive intervention group
were significantly more likely to be confirmed abstinent at 6-month follow-up: 21.3% versus 6.8% in the minimal
intervention group (chi-square  5.21, p  0.023).
Conclusions Many long-term smokers with PAD are willing to initiate a serious quit attempt and to engage in an intensive
smoking cessation program. Intensive intervention for tobacco dependence is a more effective smoking cessa-
tion intervention than minimal care. Studies should be conducted to examine the long-term effectiveness of in-
tensive smoking cessation programs in this population to examine the effect of this intervention on clinical out-
comes related to PAD. (J Am Coll Cardiol 2010;56:2105–12) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.07.031f
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wtherosclerotic peripheral arterial disease (PAD) is a highly
revalent disorder that affects between 5% and 10% of U.S.
dults 40 years of age (1–3). PAD is a major cause of
isability in many persons. It often decreases functional
apacity because of exercise-associated limb pain (claudi-
ation) and, if untreated, may progress to critical limb
schemia, defined as ischemic rest pain, gangrene, or
mputation (4,5).
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roject was supported by funds from ClearWay Minnesota, Bloomington, Minnesota
Grant No. RC-2005-0039). Dr. Duval has received a research grant from Abbott
ascular. All other authors have reported that they have no relationships to disclose.P
Manuscript received March 31, 2010; revised manuscript received June 25, 2010,
ccepted July 6, 2010.Cigarette smoking is the single most important risk factor
or the development and progression of PAD (1,2,6,7). A
eta-analysis of 17 studies found a 2.2-fold greater preva-
ence of symptomatic PAD in smokers compared with
onsmokers (7). Continued smoking accelerates the pro-
ression of stable claudication to more serious limb ischemic
AD syndromes, including critical limb ischemia, and to
atal and nonfatal systemic cardiovascular ischemic events
e.g., angina, myocardial infarction, transient ischemic at-
ack, and stroke). PAD patients who achieve abstinence
rom smoking have far higher survival rates than those who
o not (8–10).
See page 2113
Despite the importance of quitting smoking for persons
ith PAD, few studies have examined smoking cessation in
AD patients, and most that have been conducted have
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which no formal smoking cessa-
tion program was provided (11,12).
One randomized study has been
conducted: Galvin et al. (13) tested
the effectiveness of nurse-conducted
smoking cessation education pro-
gram and the use of nicotine gum,
a pharmacological aid for smoking
essation, but the sample size was very small and the end point
as smoking reduction rather than smoking cessation. This
tudy found a significant difference between the intervention
nd control groups in self-reported number of cigarettes
moked, but tests of 2 biomarkers of tobacco use, expired
arbon monoxide and urinary cotinine, a metabolite of nico-
ine, provided conflicting results (13).
The present study tested the reach and effectiveness of an
ntensive, comprehensive smoking cessation program for
AD patients. A first objective was to examine the willing-
ess of PAD patients to enroll in an intensive program. The
econd objective was to examine program effectiveness: we
ypothesized that the 7-day point prevalence of abstinence
ould be significantly higher among patients randomly
ssigned to an intensive PAD-specific intervention condi-
ion compared with patients randomly allocated to a mini-
al intervention (usual care) control group.
ethods
ites and participants. Participants were recruited from 2
edical centers in Minneapolis, Abbott Northwestern Hos-
ital and the Minneapolis Veterans Administration Medical
enter (VAMC). All participants provided written in-
ormed consent, and the study was approved by institutional
eview boards at the University of Minnesota, the VAMC,
nd the Allina Health System.
Primary inclusion criteria were a diagnosis of lower
xtremity PAD (defined as at least 1 of the following: an
nkle-brachial index of 0.90 in at least 1 lower extremity;
oe brachial index of 0.60; objective evidence of arterial
cclusive disease in 1 lower extremity by duplex ultrasonog-
aphy, magnetic resonance angiography or computed tomo-
raphic angiography; prior leg arterial revascularization or
mputation due to PAD; and current smoking [defined as
moking at least 1 cigarette a day at least 6 days per week]).
dditional inclusion criteria included a desire to quit within
he next 30 days, age 18 years or older, ability to speak and
rite English, no participation in a smoking cessation
rogram in the past 30 days, and consumption of fewer than
1 alcoholic drinks per week.
rocedures. Between July 2006 and May 2008, study staff
dentified potentially eligible patients who were scheduled
or upcoming visits at the recruitment sites from appoint-
ent lists and electronic medical records. We sent patients
etters describing the study and screened them either by
Abbreviations
and Acronyms
PAD  peripheral arterial
disease
VAMC  Veterans
Administration Medical
Centerelephone before an upcoming medical appointment or in eerson at the visit to determine eligibility for the study.
nterested and eligible patients underwent the informed
onsent process with the study coordinator at the clinic visit
nd completed a baseline survey. We randomized partici-
ants using a predetermined block randomization schedule
tratified by medical center to either the intensive smoking
essation intervention group or to the minimal intervention
roup.
Follow-up surveys were mailed to participants 3 months
nd 6 months after baseline survey completion. We mailed
second copy of the survey with a reminder letter to
articipants who had not returned the initial copy. If the
urvey was still not returned, we contacted the participant by
elephone to request survey completion. At the 6-month
ollow-up, we sent participants who did not return the
urvey after these contacts a 1-page version of the survey
hat measured the smoking outcome only. Participants
eporting abstinence from cigarettes at 6 months were asked
ither to provide a saliva sample to test for cotinine (a
etabolite of nicotine) or, if they were using nicotine
eplacement products, to provide an expired air sample to
est carbon monoxide levels to verify self-report. Saliva was
ollected by mail; we mailed a second saliva collection kit to
articipants who did not return a saliva sample within 9 to
2 days after the initial mailing. This method of collecting
aliva samples for biochemical verification has been used in
revious studies (14). We conducted carbon monoxide
esting in person, generally at the participant’s home.
ntervention. INTENSIVE INTERVENTION GROUP. The in-
ensive smoking cessation intervention included both physician
dvice to quit smoking and smoking cessation counseling
rovided by a study counselor. Vascular clinic care providers
ere cued to provide cessation advice by a prompt in partici-
ants’ medical charts. In addition, we sent participants in the
ntensive intervention group an individualized letter from a
ascular healthcare provider at the site where they were
eceiving care advising them to quit smoking and emphasizing
he importance of quitting for patients with PAD.
The counseling intervention included behavioral and phar-
acological components that are evidence-based in the general
opulation of smokers. Counseling consisted of a combination
f education about the link between smoking and the onset
nd progression of PAD, motivational interviewing to increase
otivation to quit (15), cognitive-behavioral counseling to
evelop a quit plan (16), and provision of information about
harmacological aids for smoking cessation. Counselors used a
ognitive-behavioral, problem-solving skills training approach
o help patients select a target quit date, prepare for quitting,
nd identify personally relevant behavioral and cognitive strat-
gies for coping with urges to smoke (16). They encouraged
articipants to use stop-smoking medication aides and pro-
ided information about available types of medication and how
o obtain them through their health insurance or their health-
are provider. They also asked patients to select a person in
heir social network who could actively support their quit
fforts. If the patient nominated a support person and gave
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December 14/21, 2010:2105–12 Smoking Cessation Program for PAD Patientsermission to do so, the counselor contacted the support
erson by telephone early in the counseling process to discuss
trategies to provide effective support to the participant.
We planned to deliver a minimum of 6 counseling sessions
ver a period of 5 months, but more were allowed when
articipants desired them. The initial visit with the counselor
enerally occurred in person; subsequent visits occurred either
n person or by telephone, at the participant’s convenience.
Counselor training for the study included education
bout tobacco addiction, counseling techniques, pharmaco-
ogical aids for smoking cessation, and the intervention
rotocol; it culminated in role plays of counseling situations.
e conducted monthly meetings with counselors through-
ut the study to discuss individual cases.
INIMAL INTERVENTION GROUP. As in the intensive con-
ition, participants in the minimal intervention received
erbal advice to quit smoking from their vascular provider
rompted by a form in the medical chart. The study
oordinator gave participants in this group a list of smoking
essation programs and resources in their community.
hese participants did not receive a letter from a vascular
rovider encouraging them to quit smoking nor did they
eet with a study smoking cessation counselor.
easures. SMOKING STATUS. The primary tobacco use
utcome measure was 7-day point prevalence of smoking
i.e., “Have you smoked a cigarette, even a puff, in the past
days?”) (17), at the 3-month and the 6-month follow-up.
t the 6-month follow-up, saliva samples were tested using
icAlert test strips (Nymox Corporation, Hasbrouck
eights, New Jersey). NicAlert levels of 1 or more (i.e.,
10 ng/ml) were considered disconfirming values. Carbon
onoxide levels 8 ppm were considered indicative of
moking. Persons who did not provide a self-report of
moking status (i.e., were lost to follow-up) or for whom
iochemical verification of smoking status could not be
btained were classified as smokers.
SE OF PHARMACOLOGICAL AIDS FOR SMOKING CESSATION.
n each survey, participants were asked whether they had
sed each of 7 medications that are the most commonly
sed pharmacological aids for smoking cessation: the nico-
ine patch, nicotine gum, nicotine lozenge, nicotine inhaler,
icotine nasal spray, bupropion hydrochloride (Zyban), and
arenicline (Chantix). Participants were asked whether they
ad ever used these medications and whether they used
hese medications between study enrollment and the
-month follow-up, and, if so, for how many days.
THER SMOKING-RELATED MEASURES. Measures of smok-
ng history, current attitudes and practices related to smok-
ng, and social context of smoking were administered at
aseline. These measures included number of cigarettes
moked per day (daily smokers) or per week (nondaily
mokers); age of initiation of smoking; level of addiction to
icotine (18), previous participation in a formal smoking
essation program; reduction of smoking and the number of iuit attempts lasting at least 24 h in the previous year; and
evel of self-efficacy for cessation measured by a single item
hat asked participants to rate on a scale from 0 to 10 their
onfidence that they could quit permanently if they decided
o do so. Questions about participant beliefs included 4
tems adapted from a number of sources (19–21) that
valuated the subject’s level of concern about PAD (“I am
oncerned about my circulation problems/peripheral artery
isease”); PAD-specific risk of smoking (“My circulation
roblems are not related to cigarette smoking” and “Con-
inued smoking would seriously harm my long-term
ealth”); and the importance of quitting (“With the health
roblems I have, I really need to quit smoking now”).
esponse options for these questions were strongly disagree,
isagree, agree, or strongly agree. Measures of the social
ontext of smoking were the number of other smokers in the
ubject’s household; smoking status of the spouse or partner;
he number of close friends who smoke (response options:
lmost all, more than half, about half, less than half, almost
one, none); and perceived level of support for quitting
moking measured separately for family and friends (re-
ponse options: a scale of 1 to 5, where 1 means “not at all
upportive” and 5 means “extremely supportive”).
EMOGRAPHIC AND HEALTH-RELATED MEASURES. De-
ographic characteristics measured at baseline included age,
ex, ethnicity, marital status, and education level. Health-
elated measures included a measure of depression, the
0-item version of the Center for Epidemiological Studies
epression Scale (CES-D) (22) and a Short Form (36)
ealth Survey (SF-36) item questionnaire that measures
he subject’s perception of his/her general health (response
ptions: excellent, very good, good, fair, poor) (23).
ntervention process. The study counselors recorded the
umber of counseling sessions completed and the length
nd site of each session.
nalyses. We first examined differences between the study
roups for factors that could be potential confounders in the
ain outcome analysis, using t tests for continuous variables
nd chi-square tests for categorical variables. The variables
ested are listed in Table 1. Because we found no differences
etween the groups on potential confounders, we used
hi-square to test the relationships between study group and
moking status at follow-up and use of pharmacological aids
or smoking cessation during the study period. Analyses of
ollow-up smoking status were intent to treat: participants
ho were lost to follow-up (self-report and validated mea-
ures) or who did not provide samples to validate self-report
f abstinence (validated measure) were considered smokers.
e did not adjust alpha levels to account for testing at both
- and 6-month follow-up.
esults
igure 1 provides an overview of recruitment, eligibility, and
urvey completion. Of the 687 participants who were
dentified from records as patients with PAD who were
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Smoking Cessation Program for PAD Patients December 14/21, 2010:2105–12urrent smokers, 583 (85%) were screened for eligibility,
nd 232 (34% of those identified and 40% of those screened)
et all eligibility criteria for the study. Fifty-three percent of
AD Tobacco Study Baseline Characteristics of Intensive InterventTable 1 PAD Tobacco Study Baseline Characteristics of Intens
Site
Abbott Northwestern
VAMC
Sociodemographic characteristics
Mean (SD) age
Sex
Male
Female
Race
White
Other
Education
High school degree or less
Vocational training or some college
College or university undergraduate or graduate degree
Marital status
Married or living together
Not married
General health
Depression (CES-D-10 total score 10)
General health judged fair or poor (SF-36 item)
Tobacco-related variables
Mean (SD) age of starting smoking
Mean (SD) cigarettes per day
First cigarette of morning within 30 min of waking
Mean confidence can quit (11-point scale)
Believe that his/her PAD is related to smoking (agree or strongly agree)
Believe that continued smoking would seriously harm his/her long-term health
(agree or strongly agree)
Cut back smoking in past year
One or more quit attempt in past year
Previous participation in a quit program
Previous use of some type of NRT (patch, gum, lozenge, inhaler, or nasal spray)
Previous use of bupropion
Previous use of varenicline
Any other smokers in household
Spouse smokes
Number of close friends who smoke
Almost all
Some
None or almost none
Perceived support for quitting from family
Extremely supportive
Somewhat supportive
Not supportive
Perceived support for quitting from friends
Extremely supportive
Somewhat supportive
Not supportive
esults are expressed as n (%) or mean (SD).
CES-D  Center for Epidemiologic Studies Depression Scale; NRT  nicotine replacement therahose eligible for the study consented to participate. Among ponfirmed smokers, the most common reason for ineligibil-
ty was not wanting to quit in the next 30 days (n  171).
f these 171 patients are included in a calculation of the
roup and Minimal Intervention (Control) Grouptervention Group and Minimal Intervention (Control) Group
nsive Intervention
(n  64)
Minimal Intervention
(n  60)
Test of Difference Between Groups
p Value
0.91
23 (36) 21 (35)
41 (64) 39 (65)
59.8 (7.1) 60.7 (9.0) 0.53
0.38
53 (83) 53 (88)
11 (17) 7 (12)
0.27
58 (92) 58 (97)
5 (8) 2 (3)
0.33
18 (28) 17 (28)
38 (59) 40 (67)
8 (13) 3 (5)
0.29
27 (42) 31 (52)
37 (58) 29 (48)
19 (32) 15 (28) 0.61
34 (54) 32 (54) 0.98
15.7 (3.5) 15.8 (3.3) 0.87
18.8 (10.7) 17.5 (12.8) 0.74
59 (92) 53 (88) 0.47
6.1 (2.6) 6.4 (2.5) 0.53
45 (74) 41 (72) 0.82
59 (97) 57 (97) 0.38
44 (69) 39 (65) 0.66
47 (73) 39 (65) 0.31
16 (25) 9 (15) 0.17
52 (81) 52 (87) 0.41
30 (47) 26 (44) 0.76
11 (20) 14 (27) 0.40
28 (65) 28 (62) 0.78
17 (27) 15 (25) 0.55
0.61
13 (20) 14 (24)
35 (55) 27 (46)
16 (25) 18 (31)
0.20
39 (65) 44 (76)
14 (23) 12 (21)
7 (12) 2 (3)
0.48
30 (48) 25 (45)
23 (37) 26 (46)
9 (15) 5 (9)
36  Short Form (36) Health Survey; VAMC  Veterans Administration Medical Center.ion Give In
Interoportion of confirmed smokers interested in quitting
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ndicated interest in quitting immediately.
Of the 124 enrolled in the study, 64 were randomized to
he intensive intervention group and 60 to the minimal
ntervention group. Four participants who died during the
ourse of the study (3 in the intensive intervention group
nd 1 in the minimal intervention group) were not included
n computation of survey completion rates or analyses of
tudy outcomes. Survey completion rates for the 2 groups
ere similar at 3-month follow-up, but the completion rate
f the minimal intervention group was higher at 6-month
ollow-up than that of the intensive group (83% vs. 75%).
articipant characteristics. Table 1 presents characteris-
ics of the participants and displays differences at baseline
etween the intensive and minimal intervention groups.
articipants were predominantly male (85%) and Caucasian
94%); the mean age was 60 years (range 40 to 81 years).
hey smoked a mean number of 20 cigarettes per day, and
0% smoked their first cigarette of the day within 30 min of
aking. These data suggest that most of the participants
ad a high level of nicotine dependence. Reponses to
uestions about beliefs concerning smoking indicated that
lmost all of the participants believed that smoking posed a
isk to health and that it was important for their health to
uit smoking immediately. The majority of participants had
ried to quit and had cut back on smoking during the past
ear and most had used pharmacological aids for smoking
essation, but only 20% had ever participated in a formal
moking cessation program. Most were not confident that
Figure 1 Diagram of Recruitment, Randomization, and Survey R
Of patients identified from records as diagnosed with peripheral artery disease (PA
all eligibility criteria for the study. Fifty-three percent of those eligible consented to
the minimal intervention group. Survey completion rates for the 2 groups were sim
was higher at 6-month follow-up than that of the intensive group (83% vs. 75%).hey could quit smoking. The majority of participants lived 0ith other smokers and had close friends who smoked.
hey reported that their family members were extremely
upportive of their quitting smoking, but indicated that they
ad less support from friends. Finally, one-half of partici-
ants reported only fair or poor health and a relatively large
roportion (30%) scored as depressed on the CES-D-10.
e found no significant baseline differences in these vari-
bles between participants randomly assigned to the inten-
ive and minimal intervention groups.
ntervention fidelity. Participants were receptive to coun-
elor contact: only 2 could not be contacted for counseling,
nd the median number of sessions was 8.5 (range 0 to 18).
wenty-six percent of sessions were completed in person;
he remainder was completed by phone. Median length of
essions was 20 min. The median total time for counseling
essions per patient was 3.2 h, but the total time was quite
ariable ranging from 20 min to 10.8 h among the patients
ho were reached for counseling.
edication use. Table 2 describes differences between the
ntensive and minimal intervention groups in the use of
harmacological aids for smoking cessation during the study
eriod as reported on the 6-month follow-up survey. Inten-
ive intervention group participants reported significantly
ore use of pharmacological aids for smoking cessation
uring the study period. At 6-month follow-up, 87% of
ntensive intervention group participants reported using
harmacological aids for smoking cessation during the
eriod between the baseline and 6-month surveys whereas
7% of minimal intervention participants did so (p 
n Rates
smokers and screening for study eligibility, 232 (40% of those screened) met
ipate; 64 were randomly allocated to the intensive intervention group and 60 to
3-month follow-up, but the completion rate of the minimal intervention groupetur
D) and
partic
ilar at.024). Among those who used medications, the proportion
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Smoking Cessation Program for PAD Patients December 14/21, 2010:2105–12ho used nicotine replacement products was roughly similar
etween the 2 groups, but intensive intervention partici-
ants were significantly more likely to have used varenicline
54.4% vs. 30.6% in the minimal intervention group, p 
.019). The median number of days of reported medication
se for those who used medication was 47.5 for intensive
ntervention participants and 13.0 for minimal intervention
articipants.
moking abstinence. Table 3 presents 7-day point preva-
ent abstinence at 3- and 6-month follow-up. Intent-to-
reat self-report data are provided for both follow-up peri-
ds and biochemically verified results are provided for the
nal follow-up. Participants lost to follow-up and therefore
ounted as smokers numbered 30 at 3-month follow-up (16
n the intensive group and 14 in the minimal group) and 25
t 6-month follow-up (15 in the intensive group and 10 in
he minimal group). Of the participants who reported
bstinence on the 6-month follow-up survey, 4 (2 in each
ondition) did not provide samples for biochemical confir-
ation, and the reports of 5 (3 in the intensive condition
nd 2 in the minimal condition) who did provide samples
ere not confirmed by the biochemical tests. These partic-
pants were also counted as smokers in analyses.
At 6-month follow-up, intensive intervention partici-
ants were significantly more likely to be abstinent than
inimal intervention participants: verified quit rates at
-month follow-up were 21.3% in the intensive intervention
roup versus 6.8% in the minimal intervention group
chi-square  5.21, p  0.023). This effect was evident at
oth of the study sites: verified quit rates for minimal and
ntensive groups were 4.8% versus 13.7%, respectively, at
Percentage of Participants Who Reported Use ofor Smoking Cessation During Study Period on 6Table 2 P rcentage of Participants Who Refor Smoking Cessation During Study
Intervent
(n  46
Used any medication 87.0
Used nicotine replacement medication 45.6
Used bupropion 8.7
Used varenicline 54.4
Note: 29 participants who did not complete the 6-month survey could n
in the minimal intervention group) did not return the survey and 4 die
elationship Between Study Condition and Abstinence at 3- and 6-Table 3 Relationship Between Study Condition and Abstinence
Group
3-month follow-up: self-report intent-to-treat analysis
Intensive 6
Minimal 5
6-month follow-up: self-report intent-to-treat analysis
Intensive 6
Minimal 5
6-month follow-up: biochemically verified intent-to-treat analysis
Intensive 6
Minimal 5ote: 4 participants who died before the 6-month survey were excluded from analyses.bbott Northwestern and 7.8% versus 25.6% at the
AMC.
iscussion
he key findings of this study are that many patients
ith PAD who are current smokers are interested in
uitting and receptive to a formal smoking cessation
rogram, and a significant proportion can quit when
rovided with resources to do so. Interest in quitting was
eflected in the high proportion of participants who had
ut back on the amount they smoked or had tried to quit
moking in the year before the study and the fact that
ost participants had previously used pharmacological
ids for smoking cessation. About a third of confirmed
mokers in this group indicated interest in quitting
moking immediately.
Participant responses to questions on the baseline survey
bout their beliefs about smoking and health were also
onsistent with a desire to quit: study participants almost
niversally indicated an understanding of the risk of smok-
ng to their health and the need to quit immediately.
inally, the desire to quit was demonstrated by the high
evel of engagement in counseling among those assigned to
he intensive intervention condition. These data reinforce
he importance of providing critical resources to these “at
isk” but highly motivated patients.
These patients with PAD were confronted with consid-
rable obstacles to smoking cessation including high levels
f addiction to smoking. For example, 90% of participants
n this study reported smoking the first cigarette of the day
rmacologic Aidsth Survey (n  95)d Use of Pharmacologic Aids
iod on 6-Month Survey (n  95)
Control
(n  49) Chi-Square p Value
67.4 5.127 0.024
32.7 1.686 NS
20.4 2.590 NS
30.6 5.484 0.019
cluded in analyses; 25 (15 in the intensive intervention group and 10
e the survey.
h Follow-Up- and 6-Month Follow-Up
Abstinent
n (%) Chi-Square p Value
13 (21.3)
4 (6.8) 5.21 0.023
19 (31.2)
6 (10.2) 8.00 0.005
13 (21.3)
4 (6.8) 5.21 0.023f Pha-Monporte
Per
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December 14/21, 2010:2105–12 Smoking Cessation Program for PAD Patientsithin 30 min of waking compared with 50.8% of Minne-
ota smokers in the 2006/2007 Tobacco Use Supplement to
he Current Population Survey (24). The mean number of
igarettes per day smoked by participants was 21.2, com-
ared with the mean of 13.9 cigarettes per day reported by
innesota smokers in the Current Population Survey (24).
n addition, the majority of participants lived in households
ith other smokers and many had spouses or partners who
moked, so were probably exposed to daily cues for smoking.
The results of this study suggest that providing intensive
moking cessation intervention for patients with PAD can
ignificantly increase short-term quit rates. This effect may
e due to increased use of medications by patients in the
ntensive intervention group, receipt of counseling, or both.
ntensive intervention participants were significantly more
ikely to use pharmacological aids for smoking cessation,
nd, if they did use them, to use them for a longer period of
ime. Participants in the intensive intervention group were
lso significantly more likely to use varenicline, the newest
f the medications available for smoking cessation. The
moking cessation literature reports a reluctance of many
mokers to try pharmacological aids for smoking cessation
nd, among those who do try it, frequent failure to use it
ong enough or in sufficient quantity (25,26). One benefit of
ore intensive counseling may be to encourage patients to
tart and persevere in the use of pharmacological aids for
moking cessation.
tudy limitations. The study results must be interpreted in
ight of methodological limitations. Participants were recruited
rom 2 large medical centers that provide specialty care for
atients with PAD. It is possible that this patient population is
ot representative of all patients with PAD, such as those
rimarily managed in primary care. Other important limita-
ions are the short time frame of the study, since relapse can
ccur after 6 months, and that we did not include a measure of
ore prolonged abstinence. Information about medication use
ight have been inaccurate, since it was based on recall of use
ver a 3-month period on the follow-up surveys.
Despite these limitations, these results have implications
or both medical practice and research. A significant pro-
ortion of patients diagnosed with PAD and identified as
urrent smokers in medical records was willing to initiate a
erious quit attempt and participate in an intensive smoking
essation program. It is important that healthcare providers
dvise PAD patients to quit smoking and follow-up this
ecommendation with appropriate care. The effectiveness of
ealthcare-based interventions for smoking cessation has
een well established, as reflected in the recently updated
nd evidence-based Public Health Service clinical practice
uideline for tobacco use (27). The U.S. and international
AD evidence-based guidelines uniformly offer class I
ecommendations that all clinicians offer individuals with
AD a tobacco cessation intervention (28,29).
Augmentation of standard treatment might also be called
or with this group of patients. Gritz et al. (30) suggest that
hronically ill patients who continue to smoke after diag-osis might profit from modification and tailoring of stan-
ard smoking cessation treatment designed for healthy
mokers. Patients who continue to smoke even after being
iagnosed with a chronic illness that is caused and/or
xacerbated by tobacco use are likely to be highly addicted to
icotine and might face problems with comorbidities and
ack of access to care that are not faced by healthy smokers.
ritz et al. (30) suggest modifications of treatment for this
opulation that go beyond increased intensity: including the
amily in treatment, improving access to smoking cessation
rograms, providing specially tailored materials, and ensuring
hat medical providers address tobacco use even though there
re many medical and lifestyle issues that must be addressed in
he treatment of patients with chronic illnesses. Research into
he effectiveness of these and other modifications of smoking
essation treatment for chronically ill patients is needed.
onclusions
any long-term smokers with PAD are willing to initiate a
erious quit attempt and to engage in an intensive smoking
essation program. Such engagement with an intensive
AD-specific intervention is associated with a significant
ncrease in smoking abstinence. These results indicate the
mportance of incorporating smoking cessation treatment
nto the medical management of PAD. Given high levels of
ddiction and significant barriers to quitting in many PAD
atients, treatment should include tobacco dependence
anagement that is rigorous and long-term. Future inves-
igation of a larger sample with longer follow-up should be
onducted to evaluate the impact of this intervention on
imb symptoms and systemic ischemic event rates.
eprint requests and correspondence: Dr. Deborah Hennrikus,
chool of Public Health, University of Minnesota, 1300 South
econd Street, Suite 300, Minneapolis, Minnesota 55408. E-mail:
ennr001@umn.edu.
EFERENCES
1. Agarwal S. The association of active and passive smoking with
peripheral arterial disease: results from NHANES 1999–2004. Angi-
ology 2009;60:335–45.
2. Criqui MH. Peripheral arterial disease—epidemiological aspects. Vasc
Med 2001;6 Suppl 1:3–7.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial
disease detection, awareness, and treatment in primary care. JAMA
2001;286:1317–24.
4. McDaniel MD, Cronenwett JL. Basic data related to the natural
history of intermittent claudication. Ann Vasc Surg 1989;3:273.
5. Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent
claudication: its natural course. Surgery 1975;78:795.
6. Cole CW, Hill GB, Farzad E, et al. Cigarette smoking and peripheral
arterial occlusive disease. Surgery 1993;114:753–7.
7. Willigendael EM, Teijink JAW, Bartelink ML, et al. Influence of
smoking on incidence and prevalence of peripheral arterial disease. J
Vasc Surg 2004;40:1158–65.
8. Chi UW, Jaff MR. Optimal risk factor modification and medical
management of the patient with peripheral arterial disease. Catheter
Cardiovasc Interv 2008;71:475–89.
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
K
2112 Hennrikus et al. JACC Vol. 56, No. 25, 2010
Smoking Cessation Program for PAD Patients December 14/21, 2010:2105–129. Faulkner KW, House AK, Castleden WM. The effect of cessation of
smoking on the accumulative survival rates of patients with symptom-
atic peripheral vascular disease. Med J Aust 1983;1:217–9.
0. Lassila R, Lepantalo M. Cigarette smoking and the outcome after
lower limb arterial surgery. Acta Chir Scand 1988;154:635–40.
1. Ramirez-Tortosa MC, Urbano G, Lopez-Jurado M, et al. Lifestyle
changes in free-living patients with peripheral vascular disease (Fon-
taine stage II) related to plasma and LDL lipid composition: a 15
month follow-up study. Clin Nutr 1999;18:281–9.
2. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The
influence of smoking cessation and hypertriglyceridaemia on the
progression of peripheral arterial disease and the onset of critical
ischaemia. Eur J Vasc Endovasc Surg 1997;11:402–8.
3. Galvin K, Webb C, Hillier V. Assessing the impact of a nurse-led
health education intervention for people with peripheral vascular
disease who smoke: the use of physiological markers, nicotine depen-
dence and withdrawal. Int J Nurs Stud 2001;38:91–105.
4. McBride CM, Curry SJ, Lando HA, Pirie PL, Grothaus LC, Nelson
JC. Prevention of relapse in women who quit smoking during
pregnancy. Am J Public Health 1999;89:706–11.
5. Miller WR, Rollnick S. Motivational Interviewing: Preparing People
to Change Addictive Behavior. New York: The Guildford Press, 1991.
6. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and
Dependence: 2008 update. Clinical Practice Guideline. Rockville,
MD: U.S. Department of Health and Human Services, Public Health
Service, 2008.
7. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL,
Swan GE. Measures of abstinence in clinical trials: issues and
recommendations. Nicotine Tobac Res 2003;5:13–26.
8. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The
Fagerstrom test for nicotine dependence: a revision of the Fagerstrom
tolerance questionnaire. Br J Addict 1991;86:1119–27.
9. Bloom RJ, Stevick CA, Lennon S. Patient perspectives on smoking
and peripheral vascular disease, a Veteran population survey. Am Surg
1990;56:535–9.
0. Kaufert JM, Rabkin SW, Syrotuik J, Boyko E, Shane F. Health beliefs
as predictors of success of alternate modalities of smoking cessation:
results of a controlled trial. J Behav Med 1986;9:475–89.
1. Marshall P. “Just one more. . .!” A study into the smoking attitudes
and behaviour of patients following first myocardial infarction. Int J
Nurs Stud 1990;27:375–87. c2. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for
depression in well older adults: evaluation of a short form of the
CES-D. Am J Prev Med 1994;10:77–84.
3. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey:
Manual and Interpretation Guide. Boston, MA: Nimrod Press, 1993.
4. Giovino GA, Chaloupka FJ, Hartman AM, et al. Cigarette Smoking
Prevalence and Policies in the 50 States: An Era of Change. The
Robert Wood Johnson Foundation ImpacTeen Tobacco Chart Book.
Buffalo, NY: University at Buffalo, State University of New York, 2009.
5. Etter JF, Perneger TV. Attitudes toward nicotine replacement therapy
in smokers and ex-smokers in the general public. Clin Pharmacol Ther
2001;69:175–83.
6. Shiffman S, Ferguson SG, Rohay J, et al. Perceived safety and efficacy
of nicotine replacement therapies among US smokers and ex-smokers:
relationship with use and compliance. Addiction 2008;103:1371–8.
7. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and
Dependence: 2008 Update. Clinical Practice Guideline. Rockville,
MD: U.S. Department of Health and Human Services. Public Health
Service, May 2008.
8. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA guidelines for
the management of patients with peripheral arterial disease (lower
extremity, renal, mesenteric, and abdominal aortic): a report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Writing Committee to Develop Guide-
lines for the Management of Patients with Peripheral Arterial Disease
[Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). Cir-
culation 2006;113:1474–547.
9. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG, for the TASC II Working Group. Inter-Society Con-
sensus for the Management of Peripheral Arterial Disease (TASC II).
J Vasc Surg 2007;45 Suppl S:5–67.
0. Gritz ER, Vidrine DJ, Fingeret MC. Smoking cessation: a critical
component of medical management in chronic disease populations.
Am J Prev Med 2007;33 Suppl:414–22.
ey Words: clinical trials y peripheral artery disease y smoking
essation.
